Cardiol Therapeutics logo

Cardiol Therapeutics(NASDAQ) CRDL

Market Cap$188.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-56%
5 Year-61%
1 Year+46%
1 Month-27%
$1.57
-5.72%
-0.10Today
After hours$1.56-$0.00 (-0.32%)
Cardiol Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.562026-10-01
Cardiol Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.83%USD 1.732026-09-24
1 month-27.44%USD 2.152026-09-01
3 month+48.57%USD 1.052026-07-02
Year to date+63.56%USD 0.952025-12-31
1 year+45.79%USD 1.072025-10-01
3 year+77.27%USD 0.882023-10-02
5 year-60.51%USD 3.952021-10-01
Since inception-55.63%USD 3.742019-01-15

Cardiol Therapeutics Financials at a Glance

Market Cap

$188.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$36.67M

EPS (TTM)

-$0.25

P/E Ratio

-6.30

Dividend

$0.00

Beta (Volatility)

1.38 (Average)

Price

$1.57

Volume

1,829,255.897

Open

$1.61

Previous Close

$1.56

Daily Range

$1.52 - $1.65

52-Week Range

$0.88 - $2.34

Estimated Earnings Date

Nov 12, 2026

CRDL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing innovative therapies for cardiovascular disease (CVD). The company is advancing its lead candidate, CardiolRx, through a pivotal Phase II/III clinical trial aimed at addressing complications in hospitalized COVID-19 patients and exploring its potential for treating acute myocarditis.

Products and Services
  • CardiolRx: A cardioprotective treatment for COVID-19 patients
  • Subcutaneous CardiolRx: Targeting cardiac fibrosis and inflammation in heart failure
  • Research and development of anti-fibrotic and anti-inflammatory therapies
Growth Outlook
  • Ongoing Phase II/III trial could lead to significant market opportunities
  • Expansion into heart failure treatment aligns with growing healthcare needs
  • Strong pipeline supports long-term growth potential in cardiovascular therapies
Financial Highlights
  • Recent quarterly net income of -$8.64 million reflects ongoing R&D investments
  • Cash and cash equivalents of $26.09 million provide operational runway
  • Current ratio of 5.55 indicates strong liquidity position
Cardiol Therapeutics Inc. operates in the specialized drug manufacturing sector, focusing on innovative solutions for cardiovascular diseases. The company's lead product, CardiolRx, is currently undergoing a critical clinical trial, which could position it favorably in the market. The ongoing research and development efforts are aimed at addressing significant unmet medical needs, particularly in the context of COVID-19 and heart failure. Financially, the company has shown a commitment to investing in its future, as evidenced by its substantial research and development expenses. The liquidity position remains robust, with a current ratio indicating a strong ability to meet short-term obligations. This financial stability, combined with a focused growth strategy, positions Cardiol Therapeutics Inc. as a noteworthy player in the life sciences sector.
AI Generated • Sep 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

23

CEO

David G. Elsley, MBA

Website

www.cardiolrx.com

Headquarters

Oakville, ON L6H 0G5, CA

CRDL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-180.13%

Return on Capital

-190.61%

Return on Assets

-116.08%

Earnings Yield

-15.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$188.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

120.66M

Volume

1.83M

Avg. Volume

1.24M

Financials (TTM)

Gross Profit

-CA$52.73K

Operating Income

-CA$39.22M

EBITDA

-CA$36.87M

Operating Cash Flow

-CA$24.07M

Capital Expenditure

-CA$56.85K

Free Cash Flow

-CA$24.13M

Cash & ST Invst.

CA$26.09M

Total Debt

CA$107.04K

Cardiol Therapeutics Performance Analysis

Cardiol Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 0N/A
20232023-12-31CAD 0N/A
20242024-12-31CAD 0N/A
20252025-12-31CAD 0N/A
Cardiol Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Cardiol Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.38-34.9%
20232023-12-31CAD -0.32-14.9%
20242024-12-31CAD -0.3715.7%
20252025-12-31CAD -0.28-25.6%
Cardiol Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-20.0%
Q42025-12-3140.1%
Q12026-03-31-38.5%
Q22026-06-3028.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$188.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.46M

N/A

Employees

18

N/A

Net Income

-CA$8.64M

-3.5%

EBITDA

-CA$8.93M

-7.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$26.09M

+43.4%

Total Debt

CA$107.04K

-24.9%

Accounts Receivable

CA$312.75K

+11.7%

Inventory

CA$0.00

N/A

Long Term Debt

CA$65.72K

-38.6%

Short Term Debt

CA$41.31K

+16.2%

Return on Assets

-1.16%

N/A

Return on Invested Capital

-1.49%

N/A

Free Cash Flow

-CA$4.38M

+3.8%

Operating Cash Flow

-CA$4.38M

+3.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ASRTAssertio Holdings, Inc.
$23.50+0.00%
IFRXInflaRx N.V.
$1.71-5.00%
VANIVivani Medical, Inc.
$1.22-1.61%
HYPRHyperfine, Inc.
$0.87+7.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$13.29+4.98%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.90+0.04%
NKENike
$35.15-0.71%
INTCIntel
$120.00-0.19%

Questions About CRDL

What is the current price of Cardiol Therapeutics?

Cardiol Therapeutics is trading at $1.56 per share.

What is the 52-week range for Cardiol Therapeutics?

Over the past 52 weeks, Cardiol Therapeutics has traded between $0.88 and $2.34.

How much debt does Cardiol Therapeutics have?

As of the most recent reporting period, Cardiol Therapeutics reported total debt of CA$75.42K.

How much cash does Cardiol Therapeutics have on hand?

Cardiol Therapeutics reported CA$18.38M in cash and cash equivalents in its most recent financial results.

What is Cardiol Therapeutics’s dividend yield?

Cardiol Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services